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BARD1 was identified as a protein interacting with
BRCA1 - the heterodimer formed by BRCA1 and BARD1
acts in DNA repair, RNA processing, transcription and
cell cycle regulation. BARD1 has also BRCA1-indepen-
dent functions like mediating p53-dependent apoptosis.
Additionally, BARD1 mRNA isoforms were found to be
highly expressed in most human gynecological cancers.
We report 17 different BARD1 variants, four of which
were suspected to be pathogenic, including a novel sub-
stitution (c.1361C>T) leading to amino acid change in
highly conserved ankirin domain motif, a splice mutation
(c.1315-2A/G) resulting in exon 5 skipping and a silent
change (c.1977A/G) which alters several ESE motifs in
exon 10, and results in a transcript lacking exons 2-9.
Finally we identified two unrelated patients carrying
truncating nonsense mutation in exon 8 (c.1690C>T).
Our findings suggest that BARD1 mutations may be
regarded as cancer risk alleles and warrant further investi-
gation to determine their actual contribution to non-
BRCA1/2 breast and ovarian cancer families.
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